Maxim lowered the firm’s price target on Palisade Bio (PALI) to $8 from $22.50 and keeps a Buy rating on the shares. The company reported Q3 results with a net loss of ($3.5M) and ended the period with $8M in cash on the balance sheet, which should provide runway into Q2 of 2025, the analyst tells investors in a research note. Maxim anticipates another financing in the near-term, though it remains positive on the stock given the company returning to the clinic, the promising preclinical data, and the market opportunity in ulcerative colitis, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio reports Q3 EPS ($2.32) vs. ($7.38) last year
- Palisade Bio expects cash to fund operations through 1Q25
- Palisade Bio announces first subject dosed in Phase 1 study of PALI-2108
- Palisade Bio announces data from two ex vivo studies of PALI-2108
- Palisade Bio files to sell common stock, warrants, no amount given